




A Leader in Non-Invasive
Laser Vision Correction and
Owner of Opti-K®



Opti-K®

About VIS

Better vision, faster.



Opti-K® is a patented LVC device and procedure for multiple indications. It is non-invasive, painless, repeatable and requires no operating room or post-operative pharmaceuticals. There is no damage to the epithelium, no aberrations, and no cutting, ever! Results are immediate with no downtime.



Presbyopia
1.8 billion afflicted



Hyperopia
1.96 billion afflicted



AMD
220 million afflicted



Myopia
2.6 billion afflicted
(in R&D, PPA filed with USPTO)

Optimal Keratoplasty (Opti-K)

Opti-K stands as an alternative to eyeglasses, contacts, or invasive procedures such as LASIK, PRK, SMILE, or IOL, that carry known sight threatening risks.

Its ease of use, patient acceptance and affordability, coupled with a one-year guarantee are expected to facilitate widespread adoption of Opti-K.



Our Solution: Optimal Keratoplasty (Opti-K)



Thulium Laser Energy

Unique infrared thulium fiber laser-based optical deliver system: the only one in FDA's presbyopia pipeline.

Safely and temporarily improves insipient presbyopia patients that other procedures exclude or rarely treat based on refractive errors.



Under 3 Seconds Per Eye

Rapid Opti-K procedure at 2.5 seconds per eye and from setup to completion for both eyes is under 5 minutes.

Patients have immediate results with no down time.



Affordable

Direct cost for patient will be comparable to and eventually less than eyeglasses or contacts.

Up-front cost for Ophthalmologists is lower than any other presbyopia treatments in the market given lease model and no need for a surgical suite.



Non-Invasive, Safe Pain-Free, Repeatable


Pain-free procedure with no to minimal discomfort. No aberrations or adverse events. Epithelium remains intact. No cutting, ever.

Results endure 6 months to 1 year for emmetropes, up to two years for presbyopes and up to 4 years for AMD. The procedure is safely repeatable to keep pace with age-related progression.

The Opti-K System

The Opti-K procedure does not require an operating room, it is mobile, and small (22”L X 8.5”H X 16.25”W).

At 20 procedures per day (under 5-minutes total procedure time) in a 20-day month (400 procedures per month), each Opti-K system can produce over \$3.5MM gross revenue annually.



Benefits Over Indirect Competitors

	Opti-K®	Refractive Surgeries (PRK and LASIK Variants)	Intracorneal Inlays (ICIs)	Phakic Intra-Ocular Lenses (IOLs)
Non-Invasive	✓	✗	✗	✗
Procedure Time Per Eye / In Total	2.5 seconds < 5min	3 -5 min 10-15 min	30-60 min 1 Hour	10-15 min 1-2 Hours
Pain-Free	✓	✗	✗	✗
Time to Heal and Time to Experience Visual Correction	Immediate Immediate	1-7 Days 1-4 Weeks	1-4 weeks 2-8 weeks	1-2 Weeks 1-4 Weeks
Duration of Treatment	6 months – 2 years Majority >18 months*	2+ years of Good Vision Until Cataract Develops	Years of Good Vision Until Cataract Develops	Years of Good Vision Until Cataract Develops
Potential Complications	None Infrared thulium laser thermal spots fade with no scarring or damage to epithelium.	Double Vision, Halos, Glare, Low- Light and Night Vision Challenges, Dry Eye, Flap Dislocation/Striae, More Intraocular Pressure, Corneal Scars, Epithelial Ingrowth	Halos, Glare, Low-Light and Night Vision Challenges, Infections, Inflammation, Irregular Astigmatism, Inlay Decentration, Corneal Melting, Bio-Incompatibility	Halos, Glare, Low-Light and Night Vision Challenges, Blurred/Red Eye Inflammation (Uveitis), Infections, Scarring, More Intraocular Pressure, Corneal Decomposition, Cataract Formation, Glaucoma
Repeatability	✓	✗	✗ (Removable)	✗ (Removable)
‘26 Bilateral \$ Per Patient	\$750	\$5,600	\$8,500	\$9,000
Requires Office Lane instead of Expensive Surgical Suite	✓	✗	✗	✗

The Opti-K Procedure

[CLICK HERE TO VIEW](#)



Clinical Outcomes


Patients have realized between 3-8 lines of correction in 2.5 seconds with immediate results.

Clinical data is available based on a signed non-disclosure agreement.

Over 2,000 procedures performed.



Approvals and Certifications



Commercialization Vision and Plan

\$10,000
One-Time

Set Up Fee

This one-time set up fee includes insured delivery, system installation, system calibration, and procedural training.

\$1,500
Annually

Maintenance & Repair

Beyond providing annual software updates and new accessory kits, VIS system rentals require an annual maintenance & repair agreement.

\$1,500
Monthly


Equipment Lease

The Opti-K lease program is simple and convenient, and the monthly rental payment can be covered in as few as three patients per month.

\$250 H/P
\$833 AMD

VIS receives a click fee for each procedure performed including hyperopia/presbyopia (H/P) and Age-Related Macular Degeneration (AMD) as listed above.

Opti-K Target Patient Pool By Indication



1% of the total global target market capture equates to US\$10,000,000,000.00 in revenue.

Team VIS



George Aubrey
Chief Executive Officer

President, Chairman of the board




Donald Schwall
Chief Commercial Officer

SVP, Secretary, Advisory Board



Harry Glen MD
Chief Medical Officer
Advisory Board



Lee Pannell
Chief Marketing Officer

Sales & Marketing



Dr. Stephen Klyce PhD
Domestic Scientific Director

Adj. Prof. of Ophthalmology
Mt. Sinai School of Medicine



Dr. Marguerite McDonald MD
Key Opinion Leader

Clinical Prof. of Ophthalmology
NYU & Tulane



Jerry Rein, BSc
Engineering Director

Engineering



RQC Partners
Regulatory / GxP

Global



NEMKO
Auditor

Global




Sterling
Institutional Review Board

United States

Series A Offering

- Securities Offered: Convertible Preferred Shares, Series D ("Preferred Shares").
- Subject to a minimum of \$100,000 and a maximum of \$20,000,000.
- Interest: 10% simple interest per annum, accrued from the Closing Date and payable upon conversion, redemption, or maturity. Conversion:
 - Automatic conversion into Common Shares upon the earlier of (i) a Qualified IPO or (ii) the three-year maturity date.
 - Conversion price equal to the lower of (i) \$30.00 per share or (ii) a price based on the Valuation Cap.
 - Preferred to Common Shares on a 1:1 basis, subject to anti-dilution protections (broad-based weighted average).
- Maturity: Three (3) years from the Closing Date, at which time the Preferred Shares will automatically convert into Common Shares at the then-applicable conversion price, plus accrued interest. Closing Date: On or before December 31, 2026, at 5:00 PM Eastern Time

Ask and Use of Proceeds



Exit Strategy

Strategic Acquisition

- Primarily, VIS will source an acquisition by a larger strategic partner in the sector that can scale globally. This would preferably begin as a minority acquisition to begin scaling Opti-K® through the equity partner to confirm the relationship is viable. Based on negotiation, the partner company would have the ability to acquire a majority position in a cash/equity split, allowing VIS investors to receive a cash buyout while maintaining a percentage equity position in the parent company to benefit from all future scaling and sales growth on a global basis while diversifying risk through the parent company portfolio.

Initial Public Offering

- Secondly, public markets have become a popular vehicle for various transactions. Through an IPO, a private company can become a publicly traded company with more certainty as to pricing and control over deal terms. This would allow for equity valuation growth before any sale and would also be positioned as a strategic acquisition by a larger partner in the sector that can scale globally.

vis

Opti-K

Donald B. Schwall, Jr.
Chief Commercial Officer

2800 Dallas Parkway
Plano, TX 75093

(412) 908-9162

vision@viscorrect.com

www.viscorrect.com



*Opti-K*TM